Exosome Diagnostics Achieves ISO 13485:2016 Certification
June 13, 2018 07:07 ET | Exosome Diagnostics
Waltham, MA, June 13, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced that it has achieved ISO 13485:2016 certification for their Munich location, upgraded from the ISO 13485:2003...
Exosome Diagnostics Announces Bladder Cancer Surveillance Panel
May 22, 2018 08:09 ET | Exosome Diagnostics
Waltham, MA, May 22, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today completion of its pre-clinical validation of a urine-based, gene expression panel intended for use as a...
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
May 17, 2018 12:47 ET | Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
May 15, 2018 09:52 ET | Exosome Diagnostics
Waltham, MA, May 15, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. received great interest from their presentations at the International Society for Extracellular Vesicles (ISEV) 2018 in...
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
May 09, 2018 08:03 ET | Exosome Diagnostics
Waltham, MA, May 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx®...
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test
May 08, 2018 06:30 ET | Exosome Diagnostics
Waltham, MA, May 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has expanded its urology salesforce within the United States after a successful first quarter commercial launch of ExoDx...
Exosome Diagnostics Obviates Tissue Biopsies
April 17, 2018 06:21 ET | Exosome Diagnostics
Waltham, MA, April 17, 2018 (GLOBE NEWSWIRE) -- This groundbreaking observation is presented as Late Breaking Research at the AACR Annual Meeting in Chicago on Tuesday by Dr Sudipto Chakrabortty....
Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs
March 21, 2018 07:41 ET | Exosome Diagnostics
Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs.  As an internationally recognized...
Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients
March 20, 2018 07:46 ET | Exosome Diagnostics
Waltham, MA, March 20, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, recently published a study on the detection of the...
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
March 14, 2018 07:30 ET | Exosome Diagnostics
Boston, MA, March 14, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a market leader in liquid biopsy and the world’s first exosome-based diagnostics company announces a collaboration...